Gestagens in the management of prostatic carcinoma.
Two different hormonal gestagens, cyproterone acetate and norethisterone, were studied in prostatic carcinoma, for the greatest part in advanced cases. Cyproterone acetate was administered to 80, norethisterone to 38 unselected patients. The period of study extended over 2 years or more. The mechanism of action of gestagens and the role of the hormone receptors are discussed. The significance of serial measurements of plasma testosterone by providing a monitor of hormonal therapy is emphasized. The relevant literature is reviewed. The value of gestagens as an alternative to the traditional hormone therapy of prostatic carcinoma is pointed out.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017373:Cyproterone Acetate; D006801:Humans; D008297:Male; D009640:Norethindrone / Q000494:pharmacology / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011956:Receptors, Cell Surface / Q000378:metabolism; D013739:Testosterone / Q000097:blood
D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone; D009640:Norethindrone